LOGO.png
Autolus Therapeutics announces the appointment of Dr. William D. Young as a Non-Executive Director
November 15, 2021 07:00 ET | Autolus Therapeutics plc
LONDON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
LOGO.png
Autolus Therapeutics announces publication describing its small molecule-regulated CAR T cells
November 10, 2021 07:00 ET | Autolus Therapeutics plc
LONDON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
LOGO.png
Blackstone Life Sciences to invest up to $250 million in Autolus Therapeutics to develop obe-cel in adult Acute Lymphoblastic Leukemia (ALL) and advance broader platform
November 08, 2021 02:00 ET | Autolus Therapeutics plc
– One of the largest private financings of a UK biotech company, and the largest from a single source – continues Blackstone conviction in the country – Durability and favorable toxicity profile of...
Sana_Logo_RGB-72_Blue.png
Sana Biotechnology to Present Pre-Clinical Data at 2021 American Society of Hematology Annual Meeting
November 04, 2021 09:07 ET | Sana Biotechnology, Inc
SEATTLE, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that data will be...
LOGO.png
Autolus Therapeutics to Present New Data at the 63rd ASH Annual Meeting & Exposition
November 04, 2021 09:01 ET | Autolus Therapeutics plc
- Demonstrates progress on the Company’s commercial manufacturing process and builds on positive obe-cel clinical data presented at EHA Conference Call and Webcast to be held Tuesday, December 14,...
LOGO.png
Autolus Therapeutics Reports Third Quarter 2021 Financial Results and Operational Progress
November 03, 2021 07:00 ET | Autolus Therapeutics plc
LONDON, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
22157.jpg
Targeted Oncology Therapeutics: Success of CAR-T Technology for the Treatment of Haematology Cancers
November 03, 2021 05:28 ET | Research and Markets
Dublin, Nov. 03, 2021 (GLOBE NEWSWIRE) -- The "Targeted Oncology Therapeutics: Hematology Cancers" report has been added to ResearchAndMarkets.com's offering. There is a strong trend in oncology...
22157.jpg
Global CAR-T Therapy Pipeline Report 2021 with long-term Forecast to 2025 & 2030
October 29, 2021 08:08 ET | Research and Markets
Dublin, Oct. 29, 2021 (GLOBE NEWSWIRE) -- The "CAR-T Therapy Pipeline Analysis Global Market Opportunities and Strategies to 2030: COVID-19 Growth and Change" report has been added to...
LOGO.png
Autolus Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3
October 25, 2021 07:00 ET | Autolus Therapeutics plc
LONDON, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
22157.jpg
Global $6.13 Billion CAR-T Cell Therapy Markets, 2017-2020 & 2021-2026: Focus on Yescarta, Kymriah, Tecartus, Breyanzi, Abecma, Others
September 28, 2021 04:28 ET | Research and Markets
Dublin, Sept. 28, 2021 (GLOBE NEWSWIRE) -- The "Global CAR-T Cell Therapy Markets, Competition Forecast & Opportunities, 2021-2026" report has been added to ResearchAndMarkets.com's offering. ...